Rebif (human IFN-β-1a) / EMD Serono  >>  Phase 3
Welcome,         Profile    Billing    Logout  

11 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rebif (human IFN-β-1a) / EMD Serono
ACTRN12608000435381: Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study One

Active, not recruiting
3
581
 
Genzyme Corporation, Genzyme Corporation, Bayer Schering Pharma AG
Multiple Sclerosis, Relapsing-Remitting
 
 
ACTRN12608000426381: Comparison of Alemtuzumab and Rebif (registered trademark) Efficacy in Multiple Sclerosis, Study Two

Active, not recruiting
3
700
 
Genzyme Corporation, Genzyme Corporation, Bayer Schering Pharma AG
Multiple Sclerosis, Relapsing-Remitting
 
 
OPERA I, NCT01247324 / 2010-020337-99: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Checkmark CMSC 2016: OPERA I and OPERA II
Jun 2016 - Jun 2016: CMSC 2016: OPERA I and OPERA II
Checkmark AAN 2016: OPERA I & OPERA II
Mar 2016 - Mar 2016: AAN 2016: OPERA I & OPERA II
Checkmark ACTRIMS Forum 2016: Multiple sclerosis (OPERA I & OPERA II)
More
Completed
3
821
Europe, US, RoW
Interferon beta-1a, Rebif, Ocrelizumab-matching placebo, Ocrelizumab, RO4964913, Interferon beta-1a-matching placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
04/15
12/22
OPERA II, NCT01412333 / 2010-020315-36: A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Checkmark CMSC 2016: OPERA I and OPERA II
Jun 2016 - Jun 2016: CMSC 2016: OPERA I and OPERA II
Checkmark AAN 2016: OPERA I & OPERA II
Mar 2016 - Mar 2016: AAN 2016: OPERA I & OPERA II
Checkmark ACTRIMS Forum 2016: Multiple sclerosis (OPERA I & OPERA II)
More
Completed
3
835
Europe, Canada, US, RoW
Interferon beta-1a, Rebif, Ocrelizumab-matching placebo, Ocrelizumab, RO4964913, Interferon beta-1a-matching placebo
Hoffmann-La Roche
Relapsing Multiple Sclerosis
05/15
12/22
2006-004937-13: multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis

Ongoing
3
360
Europe
AZATIOPRINA HEX. 50CPR 50MG BL, REBIF SC 12SIR 6000000UI 22MCG, BETAFERON SC 15F 0,25MG 15SIR, REBIF SC 12SIR 12000000UI44MCG, AVONEX IM 4SIR 30MCG/0,5ML 4AG, AZATIOPRINA HEX. 50CPR 50MG BL, REBIF SC 12SIR 6000000UI 22MCG, BETAFERON SC 15F 0,25MG 15SIR, REBIF SC 12SIR 12000000UI44MCG, AVONEX IM 4SIR 30MCG/0,5ML 4AG
Universita di Firenze
patients with relapsing remitting multiple sclerosis
 
 
2012-005086-12: Study to investigate the ability of a blood-derived score to select patients with relapsing multiple sclerosis who benefit from treatment with human immune globulin

Ongoing
3
81
Europe
Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml, Octagam 50 mg/ml, Copaxone 20 mg/ml, Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml, Octagam 50 mg/ml, Copaxone 20 mg/ml, Rebif 44 micrograms, Betaferon 250 microgram/ml, Extavia 250 microgram/ml
Octapharma AG, Octapharma AG
relapsing multiple sclerosis
 
 
2018-001292-21: Disease modifying therapies withdrawal in inactive Secondary Progressive Multiple Sclerosis patients older than 50 years Arrêt des traitements de fond à visée immunologique chez les patients de plus de 50 ans ayant une sclérose en plaques secondairement progressive

Not yet recruiting
3
250
Europe
AVONEX, BETAFERON, EXTAVIA, REBIF, PLEDIGRY, COPAXONE, AUBAGIO, TECFIDERA, GILENYA, TYSABRI, IMUREL, NOVATREX, CELLCEPT, ENDOXAN, L03 AB 08, Concentrate for solution for injection, Powder for solution for injection, Solution for injection, Solution for injection in pre-filled syringe, Tablet, Capsule, Concentrate for solution for infusion
CHU de Rennes, CHU de Rennes
Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Secondary Progressive Multiple Sclerosis Sclérose en plaques secondairement progressive, Diseases [C] - Nervous System Diseases [C10]
 
 
2020-002060-31: An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care Mezinárodní randomizovaná studie další léčby COVID-19 u hospitalizovaných pacientů, kteří jsou léčeni standardní péčí.

Ongoing
3
100000
Europe
remdesivir, Lyophilisate for solution for infusion, Coated tablet, Powder and solution for solution for injection, Kaletra, Rebif, Plaquenil
Masaryk University, World Health Organisation, Masaryk University
COVID-19 COVID-19, COVID-19 COVID-19, Diseases [C] - Virus Diseases [C02]
 
 
DisCoVeRy, NCT04315948 / 2020-000936-23: Trial of Treatments for COVID-19 in Hospitalized Adults

Hourglass Dec 2021 - Dec 2021 : Data from DisCoVeRy trial for treatment of COVID-19 in hospitalized adults
Completed
3
1552
Europe
Remdesivir, Lopinavir/ritonavir, Interferon Beta-1A, Hydroxychloroquine, Standard of care, AZD7442, Placebo
Institut National de la Santé Et de la Recherche Médicale, France
Corona Virus Infection
07/22
09/23
NCT03283397: A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS

Recruiting
3
400
RoW
EK-12, INF beta-1a
Bosnalijek D.D, MonitorCRO
Multiple Sclerosis, Relapsing-Remitting
12/23
07/24
MIST, NCT03133403 / 2012-004165-41: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy

Recruiting
2/3
5
Europe
Tecfidera (BG12), Gilenya, fingolimod, Tysabri®, natalizumab, Avonex/Betaseron/Copaxone/Rebif, (Avonex®, Betaseron®, Copaxone®, Rebif®), Hematopoietic stem cell transplantation (HSCT)
Sheffield Teaching Hospitals NHS Foundation Trust
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
12/21
12/21

Download Options